1. Home
  2. RELY vs ARQT Comparison

RELY vs ARQT Comparison

Compare RELY & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Remitly Global Inc.

RELY

Remitly Global Inc.

HOLD

Current Price

$15.98

Market Cap

3.0B

Sector

Technology

ML Signal

HOLD

Logo Arcutis Biotherapeutics Inc.

ARQT

Arcutis Biotherapeutics Inc.

HOLD

Current Price

$22.51

Market Cap

3.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RELY
ARQT
Founded
2011
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
3.3B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
RELY
ARQT
Price
$15.98
$22.51
Analyst Decision
Buy
Strong Buy
Analyst Count
8
6
Target Price
$24.13
$34.00
AVG Volume (30 Days)
3.2M
1.2M
Earning Date
05-06-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
263.16
88.79
EPS
0.31
N/A
Revenue
$1,635,147,000.00
$376,072,000.00
Revenue This Year
$21.82
$34.46
Revenue Next Year
$19.08
$29.77
P/E Ratio
$49.31
N/A
Revenue Growth
29.37
91.34
52 Week Low
$12.08
$11.86
52 Week High
$24.63
$31.77

Technical Indicators

Market Signals
Indicator
RELY
ARQT
Relative Strength Index (RSI) 52.70 38.07
Support Level $15.62 $19.60
Resistance Level $17.81 $27.26
Average True Range (ATR) 0.61 0.90
MACD -0.21 -0.12
Stochastic Oscillator 30.25 19.56

Price Performance

Historical Comparison
RELY
ARQT

About RELY Remitly Global Inc.

Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. The company's revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.

Share on Social Networks: